NCT05933707Recruiting
Small Extracellular Vesicles and Insulin Action
Effect of Small Extracellular Vesicles From Adipose Tissue on Insulin Action
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- First submitted
- 27 Jun 2023
- Start date
- 14 Jun 2023
- Primary completion date
- 1 Jun 2028
- Lead sponsor
- Washington University School of Medicine
- Diseases
- Obesity
- NCT number
- NCT05933707
What you commit to
- Study type: Interventional
- Planned participants: 72
- From 14 Jun 2023 to the primary completion date, 1 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Take medications that could affect the study outcome measures, engage in regular exercise (\>120 min/week),
Other illness
- History of diabetes, liver disease other than NAFLD or other serious diseases,
Other
- Consume excessive amounts of alcohol (\>21 units/week for men and \>14 units/week for women),
- Are pregnant or lactating
Who the study is looking for
- Metabolically healthy lean subjects must have a BMI ≥18.5 and ≤24.9 kg/m²; Subjects with obesity must have a BMI ≥30.0 and ≤50.0 kg/m²
- Metabolically healthy lean and people with metabolically healthy obesity must have intrahepatic triglyceride (IHTG) content ≤5%; fasting plasma glucose concentration \<100 mg/dl, 2-hr oral glucose tolerance plasma glucose concentration \<140 mg/dl, hemoglobin A 1C (HbA1c) ≤5.6% and HOMA-IR \<2.5.
- People with metabolically unhealthy obesity must have intrahepatic triglyceride (IHTG) content ≥5.6%; HOMA-IR ≥2.5, and HbA1c 5.7%-6.4%, or fasting plasma glucose concentration ≥100 mg/dl, or 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≥140 mg/dl.
Age in the registry: 25 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.